Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05032040 · ClinicalTrials.gov registry record · Phase 2

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

A Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Xencor.

Active
Registry status
Phase 2
Development phase
170
Enrollment target
17
Study locations

NCT05032040 is a Phase 2 study of Ovarian Cancer and Endometrial Cancer that is active but no longer recruiting, run by Xencor. The registered enrollment target is 170 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05032040, a Phase 2 study of Ovarian Cancer and Endometrial Cancer, is active but no longer recruiting, sponsored by Xencor.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
170 participants
Enrollment target
17
Study locations

Study Summary

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Conditions Studied

Ovarian Cancer Endometrial Cancer Cervical Carcinoma Metastatic Castration-Resistant Prostate Cancer (mCRPC) Clear Cell Carcinoma

Interventions

  • BIOLOGICAL vudalimab

Study Locations (17)

California

  • UCSD Moores Cancer Center - La Jolla
  • Valkyrie Clinical Trials - Los Angeles
  • UCLA Medical Center - Los Angeles
  • Kaiser Permanente Medical Group - Riverside
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

New York

  • NYU Langone Health - New York
  • Columbia University Medical Center - New York

Arizona

  • Arizona Oncology Associates, PC - NAHOA - Prescott

Colorado

  • Rocky Mountain Cancer Centers - Aurora

Delaware

  • Medical Oncology Hematology Consultants, PA - Newark

Florida

  • Moffitt Cancer Center - Tampa

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Michigan

  • Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2022-07-21
Est. Completion 2025-12-30
Phase Phase 2

Sponsor

Xencor

27 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05032040

The ClinicalTrials.gov registry entry for NCT05032040 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which vudalimab is the first listed.

NCT05032040 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Arizona.

Frequently Asked Questions

What is clinical trial NCT05032040 about?

NCT05032040 is a clinical study titled "A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies". This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

What is the current status of trial NCT05032040?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2022-07-21. Estimated completion is 2025-12-30.

What conditions does trial NCT05032040 study?

This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Carcinoma.

What interventions are being tested in trial NCT05032040?

The interventions under investigation include: vudalimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05032040?

This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05032040 being conducted?

This trial has 17 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.